Bristol Myers Squibb Says New 5-Year Sotyktu Data Show Consistent Safety And Durable Response Rates In Moderate-To-Severe Plaque Psoriasis; No New Safety Signals Observed At Year 5 In The POETYK PSO Long-Term Extension Trial, Consistent With The Establish